MIRA Pharmaceuticals Inc. (MIRA): Aggregate Debt Obligations

MIRA Pharmaceuticals develops synthetic cannabinoid analogs to treat anxiety and pain. The company currently generates no revenue due to early-stage testing, yet the synthesis of non-narcotic molecules promises future pricing power. Total debt burden reflects the financial strain, where the 0.00 mark serves as the current indicator of credit risk on the chart.

MIRA MIRA Pharmaceuticals: Company Debts in the range 02/21/2024 - 10/30/2026

Analytical breakdowns for MIRA Pharmaceuticals (MIRA)

- stock value and consensus price forecast:

Stock Price mirapharmaceuticals.com|MIRA - Price Target Chart

- stock exchange capitalization data:

Market Value MIRA Pharma|MIRA - Enterprise Value

- book capitalization indicators:

Accounting Value per Share MIRA Pharmaceuticals|MIRA - Company Book Value|Market-to-Book Ratio mirapharmaceuticals.com|MIRA - Cumulative Company Assets

- debt obligations and liquidity statistics:

All Debt to Shareholders' Equity Ratio MIRA Pharmaceuticals|MIRA - Long-Term Debt to Capital|Current Liabilities to Equity mirapharmaceuticals.com|MIRA - Company Aggregate Debts|Debts to Book Capitalization MIRA Pharma|MIRA - Company Long-Term Debt|Company Short-Term Loans and Borrowings MIRA Pharmaceuticals|Quick Liquidity Indicator mirapharmaceuticals.com

- business earnings and investment ratios data:

MIRA - Company Net Income

General company analysis:MIRA MIRA Pharmaceuticals Inc.

Finished products of MIRA Pharmaceuticals

This indicator tracks the absolute volume of credit obligations, reflecting management's operational financial discipline through daily changes in debt load. Loan optimization frees up capital for shareholders, which is critical when financing synthetic cannabinoid research in partnership with laboratories; therefore, MIRA Pharmaceuticals (MIRA) debt levels serve as a gauge for the balance between neurology expansion and debt sustainability.

Competitors of MIRA Pharmaceuticals